Loading...
Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer
BACKGROUND: Small cell lung cancer (SCLC) is a recalcitrant malignancy with distinct biologic properties. Antibody targeting therapy has been actively investigated as a new drug modality. METHODS: We tested the expression of IGF-1R and calculated the survival in 61 SCLC patients. We also evaluated t...
Na minha lista:
| Udgivet i: | PLoS One |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Public Library of Science
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4545894/ https://ncbi.nlm.nih.gov/pubmed/26287334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0135844 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|